WebIts lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. WebThey will be a shown leader with extensive, hands-on outsourced manufacturing experience and will be responsible for recruiting, developing, and leading a team with primary accountability for...
Cytokinetics looks to muscle into the cardiovascular market
WebFeb 2, 2024 · Cytokinetics has agreed to sell 4.5% of its potential royalties from partner Amgen on potential global sales of omecamtiv mecarbil — a novel therapy aimed at … WebAug 22, 2013 · South San Francisco, CA, August 22, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of two manuscripts reporting data from two clinical trials of tirasemtiv, a novel mechanism fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis (ALS). charm city circulator water taxi
Cytokinetics Provides Development Program Update for …
WebApr 11, 2024 · Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced today three new appointments to its growing development team as the company advances ... WebMar 4, 2024 · March 4, 2024, 10:00 AM · 10 min read Cytokinetics, Incorporated Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with... WebApr 11, 2024 · 12 analysts have issued twelve-month price targets for Cytokinetics' shares. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they expect the company's stock price to reach $56.21 in the next year. This suggests a possible upside of 54.4% from the stock's current price. View analysts price targets for CYTK or view top ... charm city craft mafia holiday heap